Bayer’s top line suffered from the deconsolidation of Covestro in Q3 and was burdened by adverse FX effects (-4%). Adjusted sales were down 3% (organic: +1%) to €8,025m. The gross profit margin moved up from 67.1% to 68.0% and was clearly above the previous year’s levels. EBITDA weakened 1% to €1,969m and net profit attributable to shareholders jumped from €1,187m to €3,881m, pushed by the deconsolidated business. Operating CF of continued operations declined 2
26 Oct 2017
Losing a drag horse – guidance adjusted
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Losing a drag horse – guidance adjusted
Bayer AG (BAYN:WBO) | 0 0 0.5% | Mkt Cap: 80,975m
- Published:
26 Oct 2017 -
Author:
Martin Schnee -
Pages:
3
Bayer’s top line suffered from the deconsolidation of Covestro in Q3 and was burdened by adverse FX effects (-4%). Adjusted sales were down 3% (organic: +1%) to €8,025m. The gross profit margin moved up from 67.1% to 68.0% and was clearly above the previous year’s levels. EBITDA weakened 1% to €1,969m and net profit attributable to shareholders jumped from €1,187m to €3,881m, pushed by the deconsolidated business. Operating CF of continued operations declined 2